QPPV.COM KNOWLEDGE ASSESSMENT

Article 107i Urgent Union Procedures: Professional Knowledge Assessment

Test your understanding of the concepts covered by Article 107i Urgent Union Procedures: How Urgent Safety Action Works.

Question 1 of 10Pass mark: 80%

Question 1 of 10 New clinically important evidence becomes available while PRAC is assessing the procedure. What should the MAH do?

Withhold it until the procedure concludes to avoid disrupting the timetable Automatically submit every new item without assessing relevance Use a controlled process to evaluate its regulatory significance and communicate it through the applicable procedural framework when material Submit it only if it supports the MAH's preferred regulatory outcome

Question 2 of 10 An MAH identifies new evidence suggesting that an urgent Union procedure may be warranted. What is the most appropriate regulatory interpretation?

The MAH should formally open the Article 107i procedure itself The MAH should ignore the issue until a competent authority contacts it The MAH should assess and communicate the relevant safety information while recognising that the authority decides whether to initiate the procedure The MAH should announce a Union-wide withdrawal before any authority assessment

Question 3 of 10 Who may initiate an Article 107i urgent Union procedure under the framework described in the article?

The QPPV acting on behalf of the marketing authorisation holder The PRAC rapporteur A Member State competent authority or the European Commission, as provided by law Any marketing authorisation holder with products affected by the safety concern

Question 4 of 10 Which inspection finding would most strongly indicate effective MAH governance of an Article 107i response?

The company retained only the final label text and deleted earlier analyses to avoid confusion The company can trace the original safety information through escalation, submission, regulatory outcome, implementation and ongoing monitoring The company relied on informal conversations instead of documented decisions because the procedure was urgent The company assigned all responsibilities to one individual without documented review

Question 5 of 10 A product is associated with a potentially severe adverse reaction, but the evidence is still being evaluated and no urgent Union regulatory measure is yet being considered. What is the best conclusion?

Article 107i automatically applies because the reaction is severe The issue must be handled only through a routine variation The concern may remain within signal management or other ordinary processes until the legal and regulatory threshold for Article 107i is met The QPPV must request immediate PRAC assessment

Question 6 of 10 Which implementation approach is most consistent with the article after a legally operative urgent safety outcome?

Update only the Package Leaflet and close the safety issue Implement the final regulatory requirements and assess effects on product information, the RMP, risk minimisation, PV activities and ongoing monitoring Implement the draft PRAC recommendation immediately, even if later amended Wait for routine periodic reporting before making any required changes

Question 7 of 10 What is the most effective way to manage questions from PRAC or its rapporteurs?

Answer only the parts of the question that support the MAH's position Maintain a controlled record of the question, evidence requested, owner, deadline, analysis, review and submitted response Ask each functional department to respond independently without central coordination Provide broad background information while leaving the specific question unresolved

Question 8 of 10 A final urgent safety measure reduces immediate patient risk but leaves important questions about long-term incidence unresolved. What is the most appropriate follow-up?

Stop all monitoring because the regulatory action has addressed the risk Continue appropriate signal monitoring and risk-management activities while addressing the residual uncertainty Treat the unresolved questions as proof that the regulatory measure was invalid Remove the issue from the RMP because the procedure has ended

Question 9 of 10 What is the most appropriate objective for the MAH's initial response after an Article 107i procedure is announced?

To prepare only a proposed label change because the scientific assessment is already complete To establish the scope, affected authorisations, evidence needs, timetable and governance for a controlled referral response To wait for the final PRAC recommendation before collecting any evidence To delegate the entire response to the QPPV without cross-functional involvement

Question 10 of 10 Which statement most accurately describes the overall purpose of the Article 107i mechanism?

To provide an accelerated commercial variation route for any important product change To allow coordinated Union-level assessment and protective action when an urgent pharmacovigilance concern meets the applicable legal conditions To transfer all national regulatory authority to PRAC To ensure that every urgent concern results in withdrawal of the product

Article 107i Urgent Union Procedures: Professional Knowledge Assessment

Cookie Settings